Baxter International | BAX | Long at $35.00Baxter International NYSE:BAX , a company that primarily focuses on products to treat kidney disease and other chronic and acute medical conditions, is another name that had a very rough time through 2022 and into 2024. However, the company's projected earnings and cash flow are expected to grow from 2024 through 2027 and it currently has a 3.35% dividend. Interest rates being lowered soon will help these projections. From a technical analysis perspective, my selected simple moving average is working its way down to recapture the price for a likely reversal in the next year or two (unless company fundamentals change). The recent low in June 2024 was higher than the previous low in October 2023 (higher lows) indicating a high chance of future price improvement - but nothing is guaranteed. At $35.00, it is currently in a personal buy zone.
Target #1 - $40.00
Target #2 - $48.00
Target #3 - $51.50
Target #4 - $65.00
Target #5 - $77.00 (very long-term...)
